Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Nov;56(5):727-735.
doi: 10.1016/j.jpainsymman.2018.07.021. Epub 2018 Aug 8.

An Automated Intervention Did Not Improve Adherence to Oral Oncolytic Agents While Managing Symptoms: Results From a Two-Arm Randomized Controlled Trial

Alla Sikorskii  1 , Charles W Given  2 , Barbara A Given  1 , Eric Vachon  1 , John C Krauss  3 , Margaret Rosenzweig  4 , Ruth McCorkle  5 , Victoria L Champion  6 , Asish Banik  1 , Atreyee Majumder  1
Affiliations
Randomized Controlled Trial

An Automated Intervention Did Not Improve Adherence to Oral Oncolytic Agents While Managing Symptoms: Results From a Two-Arm Randomized Controlled Trial

Alla Sikorskii et al. J Pain Symptom Manage. 2018 Nov.

Abstract

Context: An increasing number of oral cancer treatments require patient adherence and symptom self-management.

Objectives: The report presents the effects of a medication reminder and symptom management intervention directed at patients initiating new oral oncolytic agents.

Methods: Patients (N = 272) were recruited at six comprehensive cancer centers, interviewed over the telephone after oral agent initiation, and randomized to either standard care or a medication reminder and symptom management intervention. In the intervention arm, the automated system called patients daily to remind them about taking their medications and weekly to assess 18 symptoms and refer patients to a printed Medication Management and Symptom Management Toolkit. Severity of 18 symptoms was also assessed during telephone interviews at Week 4 (midintervention), Week 8 (postintervention), and Week 12 (follow-up). Adherence was measured using the relative dose intensity, the ratio of dose taken by patient out of dose prescribed by the oncologist, and assessed using pill counts at Weeks 4, 8, and 12 and prescribing information from medical records.

Results: The relative dose intensity was high and did not differ by trial arm. Symptom severity was significantly lower (P < 0.01) in the experimental arm at Week 8 but not at Weeks 4 or 12.

Conclusion: Adherence may be less of a problem than originally anticipated, and intervention was not efficacious possibly because of already high rates of patient adherence to oral oncolytic medication during first 12 weeks. Longer follow-up in future research may identify subgroups of patients who need interventions to sustain adherence.

Keywords: Cancer; adherence; oral agents; symptom management.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors do not have any conflicts of interest - financial or other relationships - that could be perceived to influence this manuscript.

Figures

Figure 1.
Figure 1.
CONSORT diagram.
See this image and copyright information in PMC

References

    1. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28(14):2381–2388. - PMC - PubMed
    1. Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract 2014;10(3):162–167. - PMC - PubMed
    1. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012;52:275–301. - PubMed
    1. Hess LM, Louder A, Winfree K, et al. Factors associated with adherence to and treatment duration of erlotinib among patients with non-small cell lung cancer. J Manag Care Spec Pharm 2017;23(6):643–652. - PMC - PubMed
    1. Lin C, Clark R, Tu P, Bosworth HB, Zullig LL. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat 2017;165(2):247–260. - PubMed

Publication types

Substances

LinkOut - more resources